Ignite Creation Date:
2025-12-24 @ 11:59 AM
Ignite Modification Date:
2026-01-01 @ 8:38 AM
Study NCT ID:
NCT00077961
Status:
TERMINATED
Last Update Posted:
2015-03-26
First Post:
2004-02-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Sponsor:
Genzyme, a Sanofi Company
Organization: